Intriguing New Class of Antimalarial Drugs Discovered

A study team headed by Gernot Längst (University of Regensburg) and Markus Meißner (LMU Munich) has made significant progress in understanding the gene regulation of the malaria pathogen.

Malaria continues to be one of the biggest risks to world health. An estimated 247 million infections and more than 600,000 fatalities occurred in 2022, primarily in sub-Saharan Africa. Therefore, there is an urgent need for innovative research methods to make long-term advancements in treatment and prevention.

Plasmodium parasites are the cause of malaria, and people contract the disease by being bitten by an infected mosquito. The most deadly malaria species, Plasmodium falciparum, has an extremely intricate life cycle that is governed by exact gene regulation. It is essential to comprehend these regulatory mechanisms in order to target the pathogen at various developmental phases.

The group discovered that the chromatin remodeler PfSnf2L, a protein complex that controls DNA accessibility for transcription, is a crucial regulator of genes involved in different phases of the pathogen’s growth.

Our research shows that PfSnf2L is essential for P. falciparum to dynamically adjust gene expression.

Maria Theresia Watzlowik

The unique sequence and functional properties of PfSnf2L led to the identification of a highly specific inhibitor that only kills Plasmodium falciparum,

Advertisement
Markus Meißner

This inhibitor represents a new class of antimalarials, potentially targeting all life cycle stages,” adds Professor Markus Meißner, Chair Professor of Experimental Parasitology at LMU’s Faculty of Veterinary Medicine.

Malaria is one of the most adaptive diseases we face.

Gernot Längst

Also Read: Positive Outcomes From the Initial Prenatal Therapy for Spinal Muscular Atrophy

Targeting its epigenetic regulation may help prevent the emergence of parasites that are resistant to treatment or improve the efficacy of currently available medications.

The study underscores the importance of integrating epigenetics into malaria research. Future work will focus on testing small molecules that inhibit the parasite’s epigenetic machinery and exploring their effectiveness in preclinical models.

Advertisement
Markus Meißner

Source: Ludwig Maximilian University – News

Journal Reference: Watzlowik, Maria T., et al. “Plasmodium Blood Stage Development Requires the Chromatin Remodeller Snf2L.” Nature, 2025, pp. 1-7, DOI: https://doi.org/10.1038/s41586-025-08595-x.


Last Modified:

Editor's Desk

Next Post

US FDA Approves Ctexli, First Treatment for Cerebrotendinous Xanthomatosis of Mirum Pharma

Sat Feb 22 , 2025
The first medication approved by the FDA to treat CTX, a rare lipid storage condition, is Ctexli.
Ctexli FDA Approval

Related Articles